Extended Data Fig. 3: Patient responses over time in cohort 4A + 4B in the full analysis set. | Nature Medicine

Extended Data Fig. 3: Patient responses over time in cohort 4A + 4B in the full analysis set.

From: First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Extended Data Fig. 3: Patient responses over time in cohort 4A + 4B in the full analysis set.

One patient had no evaluable CLDN18.2 status and is therefore excluded from the plot (total n = 75). The last patient is missing a CPS value. CLDN18.2, claudin 18 isoform 2; CPS, combined positive score; CR, complete response; H, CLDN18.2-high; I, CLDN18.2 intermediate; PD, progressive disease; PR, partial response; SD, stable disease.

Back to article page